$58.02
+0.04 (+0.07%)
Open$57.98
Previous Close$57.98
Day High$58.02
Day Low$57.98
52W High$58.02
52W Low$8.75
Volume—
Avg Volume2.25M
Market Cap1.68B
P/E Ratio—
EPS$-2.51
SectorBiotechnology
Analyst Ratings
Hold
17 analysts
Price Target
-54.6% upside
Current
$58.02
$58.02
Target
$26.34
$26.34
$18.77
$26.34 avg
$31.12
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 545.80M | 533.51M | 481.00M |
| Net Income | 29.97M | 31.31M | 23.12M |
| Profit Margin | 5.5% | 5.9% | 4.8% |
| EBITDA | 42.09M | 36.52M | 35.99M |
| Free Cash Flow | 24.22M | 23.20M | 21.80M |
| Rev Growth | +0.6% | -0.7% | +10.6% |
| Debt/Equity | 0.27 | 0.34 | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |